In 2022, there were an estimated 18.1 million cancer survivors in the United States. As of 2020, nearly 496,000 cancer survivors were first diagnosed when they were under the age of 20. Advances in cancer treatment mean that today 85% of children diagnosed with cancer are alive at least five years after diagnosis. Many ultimately will be considered cured. As a consequence, interest is growing in the long-term health of these survivors.
Health problems that develop years later because of a cancer treatment are known as late effects. (For more information, see Late Effects of Treatment for Childhood Cancer.) The Childhood Cancer Survivor Study (CCSS), funded by the National Cancer Institute and other organizations, was started in 1994 to better understand these late effects, increase survival, and minimize harmful health effects. Greg Armstrong, M.D., M.S.C.E., at St. Jude Children’s Research Hospital in Memphis, Tenn., is the principal investigator for this research study. A list of collaborating institutions can be found on the CCSS website.
CCSS originally enrolled survivors diagnosed between 1970 and 1986 at participating centers in the United States and Canada. More than 14,000 survivors were surveyed and followed to evaluate their long-term health outcomes, along with approximately 4,000 siblings who served as a comparison group.
Because cancer treatments changed substantially over the following decades, the study later expanded to include additional survivors diagnosed between 1987 and 1999, along with approximately 1,000 of their siblings. Together, these 25,735 survivor participants and 5,045 siblings represent three decades of childhood and adolescent cancer survivors.
Researchers gathered information from the survivors’ medical records on primary treatment exposure that included surgery, radiotherapy, chemotherapy, or a combination of treatments.
CCSS is an excellent resource for the development, testing, and dissemination of intervention strategies to improve the quality of life for childhood cancer survivors. Several randomized intervention studies among high-risk childhood cancer survivor populations have been completed (e.g., studies about breast cancer screening, cardiovascular screening, skin cancer screening, and smoking cessation). CCSS-based research provided the foundation for all of these studies. Intervention studies are ongoing to reduce obesity in survivors of acute lymphoblastic leukemia and to reduce the underdiagnosis and undertreatment of traditional cardiovascular risk factors—including hypertension, diabetes mellitus, dyslipidemia, improving insomnia, promoting breast cancer screening in young women, and improving communication on health issues with primary care providers. Find more information about the ongoing intervention trials.
Researchers who have studied CCSS data so far have identified a number of potential late effects, including premature menopause, stroke, cardiac side effects, and subsequent cancers such as breast cancer and skin cancer. Researchers have used the information from CCSS to develop risk prediction calculators for a variety of late effects that your doctor can use to help you understand if you are at risk for a particular late effect. Childhood cancer survivors should get close, long-term follow-up from doctors who know about these kinds of complications, say experts. To address this issue, the Children’s Oncology Group (COG) has prepared a resource for physicians called “Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers”.
The CCSS website includes a comprehensive list of published results of CCSS-based research studies.